Brokerages Set Biodesix, Inc. (NASDAQ:BDSX) PT at $3.06

Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have received a consensus recommendation of "Buy" from the seven analysts that are presently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $3.06.

BDSX has been the subject of a number of recent research reports. Craig Hallum started coverage on Biodesix in a research note on Friday, July 26th. They issued a "buy" rating and a $3.00 target price for the company. Scotiabank began coverage on shares of Biodesix in a research report on Monday, September 16th. They set a "sector outperform" rating and a $3.00 price objective for the company.

Institutional Investors Weigh In On Biodesix

A number of institutional investors have recently made changes to their positions in the stock. Perkins Capital Management Inc. boosted its position in shares of Biodesix by 74.7% during the 3rd quarter. Perkins Capital Management Inc. now owns 724,782 shares of the company's stock worth $1,290,000 after purchasing an additional 310,000 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Biodesix during the second quarter worth $3,326,000. CVI Holdings LLC acquired a new stake in shares of Biodesix in the second quarter valued at $59,000. Farallon Capital Management LLC acquired a new stake in shares of Biodesix in the second quarter valued at $2,874,000. Finally, AIGH Capital Management LLC raised its holdings in shares of Biodesix by 74.0% in the 2nd quarter. AIGH Capital Management LLC now owns 5,779,812 shares of the company's stock valued at $8,843,000 after buying an additional 2,458,727 shares during the period. 20.96% of the stock is currently owned by institutional investors and hedge funds.

Biodesix Price Performance

Shares of NASDAQ:BDSX traded down $0.40 during trading on Friday, reaching $1.30. 556,069 shares of the company's stock traded hands, compared to its average volume of 137,648. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 0.99. Biodesix has a fifty-two week low of $1.15 and a fifty-two week high of $2.21. The company has a 50-day simple moving average of $1.72 and a 200-day simple moving average of $1.61. The firm has a market cap of $188.73 million, a PE ratio of -2.83 and a beta of 1.22.

Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Friday, November 1st. The company reported ($0.07) EPS for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. The business had revenue of $18.15 million during the quarter, compared to analysts' expectations of $18.45 million. Biodesix had a negative net margin of 73.08% and a negative return on equity of 505.95%. During the same quarter in the previous year, the company earned ($0.12) earnings per share. As a group, analysts predict that Biodesix will post -0.36 earnings per share for the current year.

Biodesix Company Profile

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.